Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Genentech Girds For Competition From Generics And Big Pharma

Executive Summary

Genentech will develop a defensive plan for each of its products in preparation for the potential introduction of follow-on biologics, Exec VP-Commercial Operations Ian Clark said during an investor update meeting March 17

You may also be interested in...



Rituxan RA Approval Raises The Stakes, But With A Lower Price

Genentech/Biogen Idec are pricing Rituxan (rituximab) for rheumatoid arthritis at a lower cost for most patients than the closest comparable biologic, Bristol-Myers Squibb's Orencia (abatacept)

Genentech/OSI Touting Tarceva Pancreatic Cancer Overall Survival Benefit

Genentech and marketing partner OSI are highlighting the overall survival benefit of combination use with Tarceva over gemcitabine (Lilly's Gemzar) plus placebo for treatment of advanced pancreatic cancer

Genentech Pipeline Puts Firm Ahead Of 2005 Goals, Sailing To “Horizon 2010”

As Genentech enters the final quarter of its multi-year growth plan, the firm is on track to meet or exceed the development and product approval goals set out in its "5x5" plan for the period from 1999 to 2005

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel